TY - JOUR
T1 - Commensal production of a broad-spectrum and short-lived antimicrobial peptide polyene eliminates nasal Staphylococcus aureus
AU - Torres Salazar, Benjamin O.
AU - Dema, Taulant
AU - Schilling, Nadine A.
AU - Janek, Daniela
AU - Bornikoel, Jan
AU - Berscheid, Anne
AU - Elsherbini, Ahmed M.A.
AU - Krauss, Sophia
AU - Jaag, Simon J.
AU - Lämmerhofer, Michael
AU - Li, Min
AU - Alqahtani, Norah
AU - Horsburgh, Malcolm J.
AU - Weber, Tilmann
AU - Beltrán-Beleña, José Manuel
AU - Brötz-Oesterhelt, Heike
AU - Grond, Stephanie
AU - Krismer, Bernhard
AU - Peschel, Andreas
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2024
Y1 - 2024
N2 - Antagonistic bacterial interactions often rely on antimicrobial bacteriocins, which attack only a narrow range of target bacteria. However, antimicrobials with broader activity may be advantageous. Here we identify an antimicrobial called epifadin, which is produced by nasal Staphylococcus epidermidis IVK83. It has an unprecedented architecture consisting of a non-ribosomally synthesized peptide, a polyketide component and a terminal modified amino acid moiety. Epifadin combines a wide antimicrobial target spectrum with a short life span of only a few hours. It is highly unstable under in vivo-like conditions, potentially as a means to limit collateral damage of bacterial mutualists. However, Staphylococcus aureus is eliminated by epifadin-producing S. epidermidis during co-cultivation in vitro and in vivo, indicating that epifadin-producing commensals could help prevent nasal S. aureus carriage. These insights into a microbiome-derived, previously unknown antimicrobial compound class suggest that limiting the half-life of an antimicrobial may help to balance its beneficial and detrimental activities.
AB - Antagonistic bacterial interactions often rely on antimicrobial bacteriocins, which attack only a narrow range of target bacteria. However, antimicrobials with broader activity may be advantageous. Here we identify an antimicrobial called epifadin, which is produced by nasal Staphylococcus epidermidis IVK83. It has an unprecedented architecture consisting of a non-ribosomally synthesized peptide, a polyketide component and a terminal modified amino acid moiety. Epifadin combines a wide antimicrobial target spectrum with a short life span of only a few hours. It is highly unstable under in vivo-like conditions, potentially as a means to limit collateral damage of bacterial mutualists. However, Staphylococcus aureus is eliminated by epifadin-producing S. epidermidis during co-cultivation in vitro and in vivo, indicating that epifadin-producing commensals could help prevent nasal S. aureus carriage. These insights into a microbiome-derived, previously unknown antimicrobial compound class suggest that limiting the half-life of an antimicrobial may help to balance its beneficial and detrimental activities.
U2 - 10.1038/s41564-023-01544-2
DO - 10.1038/s41564-023-01544-2
M3 - Journal article
C2 - 38110697
AN - SCOPUS:85180217029
SN - 2058-5276
VL - 9
SP - 200
EP - 213
JO - Nature Microbiology
JF - Nature Microbiology
IS - 1
ER -